Simcere Pharmaceutical Group Ltd (2096.HK) stock: key figures, P/E, revenue and dividend
Health Care · China · ISIN HK0000658531
Simcere Pharmaceutical Group Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 6.64 bn CNY | 7.73 bn CNY |
| Gross profit | 5.32 bn CNY | 7.35 bn CNY |
| EBIT | 848.00 m CNY | 1.81 bn CNY |
| Net income | 733.00 m CNY | 1.34 bn CNY |
| Diluted EPS – continuing operations | 0.29 CNY | 0.62 CNY |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Simcere Pharmaceutical Group Ltd
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clinical trials. The company also develops SIM0270, a new-generation oral SERD with blood-brain barrier penetration characteristics; Denlorlatinib; SIM0395, a BBB-penetrant inhibitor of the PI3K/mTOR pathway; and deuterated remdesivir hydrobromide dry suspension that are in Phase 3 clinical trial, as well as Sanbexin an injection new indication; Sanbexin a sublingual tablets; and SIM0278, a Fc fusion protein (IL2muFc) with an IL2 mutein of regulatory T cells that is in Phase 2 clinical trials. It develops SIM0237, an anti-PD-L1 monoclonal antibody fused with IL-15/IL15RXa sushi protein; Enzeshu, a suvemcitug for injection; SIM0500, a humanized trispecific antibody that targets GPRC5D/BCMA/CD3; SIM0508, a small molecule inhibitor; SIM0505, a CDH6-targeting ADC molecule; SIM0686, an ADC drug targeting FGFR2b; SIM0609, a new antibody-drug conjugate targeting CDH17; SIM0610, a bispecific antibody-drug conjugate; SIM0532, an oral, non-covalent pan-RAS inhibitor; SIM0323; and SIM0811, a small-molecule plasminogen allosteric activator that are in Phase 1 clinical trial. The company develops SIM0613; SIM0709; SIM0689; SIM0688; SIM0518; SIM0616; SIM0611; SIM0815; SIM0712; SIM0725; SIM0708; SIM0721; and SIM0722 that are in pre-clinical stage. It offers pharmaceutical ingredients; production support facility; consulting and technology; promotion; and property management. The company was founded in 1995 and is headquartered in Nanjing, China.
More stocks
- ACADIA PHARMACEUTICALS INC (ACAD)
- Sendas Distribuidora S.A. (ASAI3.SA)
- BRIGHT HORIZONS FAMILY SOLUTIONS INC. (BFAM)
- Antar Chile (ANTARCHILE.SN)
- Carl Zeiss Meditec (AFX.DE)
- CIE Automotive SA (CIE.MC)
- Yamaha Corp (7951.T)
- Multiplan Empreendimentos Imobiliários S.A (MULT3.SA)
- China Gas Holdings Ltd (384.HK)
- LEENO Industrial Inc (058470.KQ)
- Aoshikang Technology Co Ltd Class A (002913.SZ)
- StepStone Group Inc. (STEP)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.